Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management
Launched by ANN-MARIE ROSLAND · Feb 21, 2025
Trial Information
Current as of November 10, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The MPowerHub trial is a research study designed to help adults with type 2 diabetes manage their health better by using information from wearable devices like glucose and activity monitors. Many people with diabetes find it difficult to keep track of their health data and make healthy choices, which can lead to complications. This study aims to create and test a new way for participants to use their personal health information to improve their daily diabetes management, ultimately leading to better health and quality of life.
To be eligible for this study, participants must have been diagnosed with type 2 diabetes and have a recent blood test showing higher blood sugar levels. They should also be currently taking diabetes medication (but not insulin) and be able to use a simple smartphone app. Participants must own a smartphone that can access the internet and have received care for their diabetes in the past year. The study is not yet recruiting, but it offers a chance for those who qualify to learn how to better manage their diabetes and reduce the risk of complications.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Received outpatient care in the participating health system in the last 12 months
- • Has a diagnosis of type 2 diabetes mellitus (ICD10 codes E08.xx, E09.xx, E11.xx, E13.xx,O24.1x , O24.3x, O24.8x, O24.9x)
- • Last Hemoglobin A1c (HbA1c) value obtained in the last 6 months was ≥7.5%
- • Currently prescribed at least one non-insulin diabetes medication
- • Able to provide informed consent
- • Able to interact with a simple smartphone application
- • Owns or has access to a smartphone that is able to access an internet website
- • Did not participate a prior study related to this protocol
- Exclusion Criteria:
- • Originally was diagnosed with type 2 diabetes before the age of 21 years
- • Has a diagnosis of type 1 diabetes mellitus
- • Has a diagnosis of gestational diabetes without any other diabetes diagnoses
- • Is currently prescribed insulin
- • Currently is using a CGM device
- • Has a diagnosis (active or prior) of schizophrenia or other psychotic/delusional disorder
- • Has a life-limiting severe illness (e.g., chronic obstructive pulmonary disease requiring oxygen)
- • Is pregnant or planning to become pregnant within the next 6 months
- • Has other concerns that may interfere significantly with their ability to participate in the intervention (ongoing health issues, personal events, etc.)
- • Currently is enrolled in another diabetes management intervention study
About Ann Marie Rosland
Ann-Marie Rosland is a dedicated clinical trial sponsor known for her commitment to advancing medical research and improving patient outcomes. With a strong background in clinical development and regulatory affairs, she leads initiatives that emphasize innovative methodologies and ethical standards in trial design and implementation. Her collaborative approach fosters partnerships with healthcare professionals, researchers, and institutions, ensuring that trials are not only scientifically robust but also patient-centered. Through her leadership, Ann-Marie aims to contribute significantly to the discovery of effective treatments and therapies across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Ann-Marie Rosland, MD, MS
Principal Investigator
University of Pittsburgh
Carissa Low, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported